Same Indication

Lisinopril vs Pembrolizumab

Lisinopril vs Pembrolizumab: Overview

This comparison examines the pharmacological differences between Lisinopril and Pembrolizumab.

Mechanism of Action

Lisinopril: ACE inhibitor preventing conversion of angiotensin I to angiotensin II.

Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

Pharmacokinetics

Half-life: Lisinopril — 12 hours; Pembrolizumab — 26 days.

Chemical Properties

Molecular Formula: Lisinopril — C21H31N3O5.

Molecular Weight: Lisinopril — 405.4900 g/mol.

Type: Lisinopril — Small molecule; Pembrolizumab — Antibody.